BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

迈阿密 - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP )，一家目前市值为3437万美元的临床阶段生物制药公司，宣布达成一项融资协议，以支持其子公司HOPE Therapeutics, Inc.。该公司股票目前交易价格为2.85美元，显示出显著的波动性，尽管年初至今的回报率强劲达29.55%，但目前仍远低于其52周高点7.33美元。根据 InvestingPro ...

Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services ...

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics.

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in almost three weeks, drawing heavy ...

The Company has recently announced execution of an agreement for $27 million in funding for HOPE Clinic Acquisition. Upon closing of the first tranch ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) recently announced significant developments regarding its private placement agreement. On January 28, 2025, NRx Pharmaceuticals, Inc. entered into an Amended ...

NRXP has entered a transformative partnership with Alvogen Pharmaceuticals for the development and marketing of NRX-101.

NRx Pharmaceuticals (NRXP) announced that it has entered into a binding agreement for a registered direct offering of its common stock with ...

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced ...

Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.

On Friday, NRX Pharmaceuticals Inc (NRXP) stock saw a decline, ending the day at $4.01 which represents a decrease of $-0.25 or -5.87% from the prior close of $4.26. The stock opened at $4.12 and ...